美女免费一级视频在线观看

    • <form id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></form>
      <address id=BiMYPaeIF><nobr id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></nobr></address>

      Merck is the latest pharmaceutical company to bring its educational disease state efforts to the baseball field.
      




      The company is rolling out its new cardiovascular health initiative, “Playing with Heart,” at the St. Louis Cardinals’ game on September 19 in St. Louis. The program focuses on atherosclerotic cardiovascular disease (ASCVD) and its risk factors — in particular, low-density lipoprotein (LDL) — what’s known as “bad cholesterol.”
      




      “The crux of [the program] is that ASCVD is a leading cause of death, and there needs to be more education and awareness around it,” noted Cristopher Regent, cardiovascular/metabolic leader of U.S. Pharma, Merck.
      




      The campaign is centered around Darryl Kile, a former Cardinals player who died in 2002 from a heart attack; as well as his daughter, Sierra Kile, and former Cardinal Adam Wainwright. The partnership with Kile and Wainwright is part of Merck’s effort to reach a captive audience during the game.
      




      The company decided to focus on St. Louis because of the city’s high rate of cardiovascular disease. According to a 2021 report from the St. Louis Department of Health, one in 450 people living in the city had a cardiovascular-related death in 2018.
      




      “The city itself has been touched by the impact of heart disease… because of what happened to Darryl Kile many years ago,” Regent said. “Heart disease is both significant and deeply felt in St. Louis.”
      




      Merck's "Playing With Heart" logo
      Image courtesy Merck; used with permission.
      




      During the game, Merck in partnership with WomenHeart will roll out an educational resource that provides information about LDL cholesterol and the importance of getting it checked with a doctor.
      




      “Heart disease has touched so many lives, including our Cardinals family,” Wainwright said in a statement. “I hope that by sharing this educational message, we can help others understand how high LDL cholesterol could increase the risk of ASCVD.”
      




      The ultimate goal of the program, Regent said, is to spur people in the stadium to set up doctor appointments to get their LDL cholesterol checked and better understand the risk factors for ASCVD.
      




      “At Merck, we believe it’s important that we provide awareness and help educate around this,” Regent said. “We [hope to] encourage them to talk to their doctor about their LDL number and to understand what’s best for them.”
      




      Merck historically established itself as a player in the cardiovascular space by developing statins since the 1980s, though in recent years it’s been seeking to invest in the heart disease sphere with non-statin medications. 
      




      A few weeks ago, Merck struck a $200 million licensing deal with Chinese biotech Jiangsu Hengru Pharmaceuticals to pick up a pill that’s being developed to target another cholesterol-related protein called lipoprotein(a) or Lp(a).
      




      The pharma is also in the process of testing a non-stain drug for LDL cholesterol, Enlicitide, which met its main goal in a late-stage trial earlier this month with patients who have hypercholesterolemia. The drug showed efficacy in lowering LDL cholesterol compared to placebo in that trial.